Semaglutide or tirzepatide: which is safer?

Free consultation reviewed the same day by a GPhC-registered Independent Prescriber, not software
ID and live weight verification included as standard, every time
Treatment dispatched the same day you're approved (order by 12pm, Monday to Friday), delivered free the next working day by DPD
Priority aftercare seven days a week — our prescribers are reachable if anything concerns you

Both semaglutide and tirzepatide have strong safety records established in large clinical trials and are licensed in the UK for weight management as prescription-only medicines — neither is categorically safer than the other. The honest answer is that their risk profiles overlap significantly, with a few meaningful differences that a prescriber weighs for each individual. As prescription medicines, they require a clinical assessment before anyone is issued a prescription; a clinician decides which is appropriate for you, taking your full health picture into account. Our clinical team works through exactly this with every patient who comes to nume.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

How the safety profiles of these two medicines actually compare

The misconception worth clearing up first

A lot of people arrive at this question assuming tirzepatide must be riskier because it works on two receptors (GIP and GLP-1) while semaglutide works on one. Two mechanisms sounds more complicated, and complicated sounds more dangerous. It's a reasonable instinct, but the clinical evidence doesn't bear it out. The SURMOUNT-1 trial, which followed thousands of adults on tirzepatide for 72 weeks, found a side-effect profile that was broadly similar to semaglutide's, dominated by the same class of gastrointestinal symptoms. Having two active pathways does not appear to translate into a meaningfully higher burden of adverse effects.

That said, "similarly safe overall" is not the same as "identical in every respect." There are genuine differences in how the two medicines interact with other drugs and in a handful of specific clinical situations, and those differences are exactly what a prescriber needs to factor in. You can read a fuller breakdown of how the two treatments compare on results and tolerability on our semaglutide vs tirzepatide comparison page.

Where the risk profiles genuinely differ

The core side-effect pattern is shared: nausea, loose stools, constipation, indigestion, reduced appetite, and occasional fatigue are reported with both medicines, particularly in the first weeks or after a dose increase. Both carry the same serious but infrequent risks, acute pancreatitis is one the MHRA highlighted in a Drug Safety Update issued for GLP-1 medicines in January 2026, advising anyone who develops severe, persistent stomach pain radiating to the back to seek urgent medical attention.

The most clinically significant difference sits in drug interactions. Women taking oral contraceptives alongside tirzepatide are advised to add a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because the pill's absorption may be reduced as the gut slows. The equivalent caution is not considered necessary with semaglutide, a distinction our page on whether semaglutide is safer than tirzepatide explores in more detail. NHS England guidance also raises the question of transdermal HRT forms for women on tirzepatide (patches or gels rather than oral tablets) worth raising with your prescriber if relevant. The NHS England guidance on weight-management injections sets this out clearly for both medicines.

Both medicines are unsuitable during pregnancy, while breastfeeding, or when trying to conceive. Neither is licensed for under-18s. Anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take either medicine.

A side-by-side view

The table below draws on data from the NHS, NICE, and published trial evidence. Numbers reflect clinical trial findings and are not guarantees of individual outcomes.

FactorSemaglutide (Wegovy)Tirzepatide (Mounjaro)
MechanismGLP-1 receptor agonistDual GIP and GLP-1 receptor agonist
Most common side effectsGI-led: nausea, diarrhoea, constipation, vomitingGI-led: nausea, diarrhoea, constipation, vomiting
Pancreatitis riskInfrequent but known; seek help for severe persistent abdominal painInfrequent but known; seek help for severe persistent abdominal pain
Oral contraceptive interactionNo specific MHRA caution identifiedAdd non-oral contraception for 4 weeks at start and after each dose increase
Pregnancy / breastfeedingNot recommendedNot recommended
Under-18sNot licensedNot licensed

Sources: NHS semaglutide medicines page; NHS tirzepatide medicines page; NICE appraisals TA875 and TA1026.

Which is the right choice for you?

There is no universal answer to the question of whether semaglutide or tirzepatide is safer, and if you want a detailed look at how to weigh up the two options, our page on which is best, tirzepatide or semaglutide, covers the key considerations side by side. Our page on choosing between semaglutide and tirzepatide covers those personal factors in more depth.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally. They consider drug interactions, contraindications, and your full clinical picture before any prescription is issued, the kind of assessment that turns the general information on this page into a decision that actually applies to you. If you want to explore your options, starting a free consultation is the place to begin. For a broader look at what's available, our weight-loss treatments overview is a good starting point.

If you'd like to understand how the two medicines compare on effectiveness rather than safety, our strength and results comparison goes into that in detail. And if cost is a factor, the Mounjaro vs Wegovy pricing page explains what you'd typically be looking at. Questions about anything here? Our team is always reachable via our contact page.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions